Spesolimab

So I think it's a huge climate need, but I also think it's a great potential to be able to step into this space and help.

And because we have the six decades of experience in dermatology, we know leo knows what we need to do we know we know we understand skin and and it's really about bringing that heritage and experience bringing the rare disease experience from other places as well connecting those two and and and continuing to build and i think in terms of our commitment if you look at what we have done over the past 12 months and now having really three assets One of them already approved, Spevigo, for GPP and being studied for other indications.

Replay, the topical gene therapy I mentioned.

And the third one now, there's Himalagon for potential treatment for EPP and XLP.